风湿骨痹口服液急性毒性研究

目的观察小鼠灌胃风湿骨痹口服液的急性毒性反应,测定半数致死量（LD50）及最大给药量,为临床安全用药提供依据。方法小鼠给予风湿骨痹口服液灌胃,通过预试验测定LD50及最大给药量。结果 LD50未测出;小鼠最大给药量为1236 g生药/kg,相当于临床人用量的1799倍,在此剂量下灌胃对小鼠无急性毒性反应。结论风湿骨痹口服液毒性较低,在临床规定用法用量下安全可靠。

Acute Toxicity of Fengshigubi Oral Liquid

Objective To observe the acute toxicity reaction of Fengshigubi Oral Liquid by gastric gavage in mice,and to determine LD50 and the maximum dosage to provide the basis for clinical safe medication. Methods The mice were given Fengshigubi Oral Liquid by gastric gavage. The median lethal dose（LD50） and the maximum dose were determined by the pre- experiment. Results LD50 was not detected out and the maximum dose in mice was 1236 g crude drug/kg,which was equivalent to 1799 times of human dosage in clinic,the gastric gavage of this dose had no acute toxicity in mice. Conclusion Fengshigubi Oral Liquid has low toxicity and it is safe under the clinical provision of usage and dosage.